<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01806090</url>
  </required_header>
  <id_info>
    <org_study_id>UCP</org_study_id>
    <nct_id>NCT01806090</nct_id>
  </id_info>
  <brief_title>Uninterrupted Clopidogrel Therapy Before Elective Colonoscopy Will Increase the Risk of Post-polypectomy Bleeding</brief_title>
  <official_title>Uninterrupted Clopidogrel Therapy Before Elective Colonoscopy Will Increase the Risk of Post-polypectomy Bleeding</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This double-blind, randomized trial aims to evaluate whether uninterrupted anti-platelet&#xD;
      therapy (clopidogrel) will increase the risk of bleeding associated with removal of polyp&#xD;
      during colonoscopy in patients with coronary artery disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Clopidogrel is a potent anti-platelet agent that, when combines with aspirin, is essential in&#xD;
      treating acute myocardial infarction and preventing coronary stent thrombosis. However,&#xD;
      adding clopidogrel to aspirin has been shown to substantially increase the risk of&#xD;
      gastrointestinal bleeding by 70%. This increased bleeding risk is a particular concern for&#xD;
      patients requiring colonoscopy. The latter is a gold standard for screening colorectal&#xD;
      cancer. This endoscopic procedure is increasingly performed for patients on anti-platelet&#xD;
      drugs because coronary artery disease is associated with increased risk of colorectal&#xD;
      neoplasia. We have shown that over 30% of patients with coronary artery disease have&#xD;
      colorectal neoplasia.&#xD;
&#xD;
      Management of patients on clopidogrel who undergo colonoscopy is a clinical dilemma.&#xD;
      Continuation of clopidogrel may increase the risk of bleeding associated with endoscopic&#xD;
      resection of polyps (post-polypectomy bleeding). This is a potentially serious complication&#xD;
      because post-polypectomy bleeding is often delayed, difficult to locate, and may provoke&#xD;
      acute coronary syndrome. Conversely, prolonged discontinuation of clopidogrel increases the&#xD;
      risk of recurrent myocardial infarction and coronary stent thrombosis.&#xD;
&#xD;
      There is a lack of prospective data on the risk of post-polypectomy bleeding attributable to&#xD;
      clopidogrel. Current American Society of Gastrointestinal Endoscopy and British Society of&#xD;
      Gastroenterology Guidelines recommend withholding clopidogrel for 7 to 10 days in planned&#xD;
      high risk endoscopic procedures such as colonoscopic polypectomy. However, this guideline is&#xD;
      largely based on retrospective data and expert opinion. In fact, the anti-platelet effect of&#xD;
      clopidogrel lasts for about 5 days only. Coronary stent thrombosis has been reported as early&#xD;
      as 7 days after stopping clopidogrel. There remains a large gap in our knowledge on the risk&#xD;
      of bleeding in patients taking clopidogrel who undergo gastrointestinal endoscopic&#xD;
      procedures.&#xD;
&#xD;
      No randomized trials have assessed whether clopidogrel should be discontinued before&#xD;
      colonoscopy. This randomized trial aims to assess whether uninterrupted clopidogrel therapy&#xD;
      during colonoscopy will increase the risk of post-polypectomy bleeding. Irrespective of the&#xD;
      outcome, this trial will be the first to provide controlled data on the risk of&#xD;
      post-polypectomy bleeding with uninterrupted clopidogrel during colonoscopy. Unfortunately,&#xD;
      this important clinical question is not a priority of pharmaceutical companies because&#xD;
      clopidogrel will be off patent soon. The outcome of this industry-independent clinical trial&#xD;
      may encourage health authorities and international guideline committees to review their&#xD;
      recommendations on the management of anti-platelet therapy for high-risk endoscopic&#xD;
      procedures.&#xD;
&#xD;
      Hypothesis Uninterrupted clopidogrel therapy increases the risk of post-polypectomy bleeding&#xD;
      in patients undergoing elective colonoscopy&#xD;
&#xD;
      Aim To investigate whether uninterrupted clopidogrel therapy before elective colonoscopy will&#xD;
      increase the risk of post-polypectomy bleeding&#xD;
&#xD;
      Study Design This is a double-blind, randomized, controlled trial in which patients receiving&#xD;
      clopidogrel for coronary stents who require elective colonoscopy will be randomized to either&#xD;
      clopidogrel or its placebo for one week prior to the endoscopic procedure&#xD;
&#xD;
      Colonoscopic Procedures Experienced colonoscopists will perform colonoscopy under conscious&#xD;
      sedation with midazolam and pethidine. Bowel preparation consists of polyethylene glycol&#xD;
      taken orally the evening and the morning before procedure together with a minimum of 2 liters&#xD;
      of clear fluids. The adequacy of bowel preparation will be documented (poor, fair, good, or&#xD;
      excellent). Colonoscopists will be instructed to remove all polyps during the colonoscopic&#xD;
      examination. The location and morphologic feature of each polyp will be recorded. The size is&#xD;
      measured using an open biopsy forceps (6 mm apart). Each lesion will be fixed in formalin and&#xD;
      sent to the pathologist for histologic evaluation. No prophylactic clips or detachable loops&#xD;
      will be applied if immediate bleeding is not observed after polypectomy. Intervention for&#xD;
      immediate post-polypectomy bleeding including injection therapy alone or in combination with&#xD;
      endoclip application, if any, will be recorded.&#xD;
&#xD;
      Follow-up assessment All patients will resume their usual prescriptions of clopidogrel after&#xD;
      colonoscopy when oral intake is allowed. They will be monitored hourly for hemodynamic&#xD;
      instability and any delayed post-polypectomy bleeding for 24 hours. After discharge, a&#xD;
      designated research nurse will contact the patients by telephone on Day 2 and Day 7 for&#xD;
      symptoms of bleeding. On Day 30, they will return for a full blood count and symptoms of&#xD;
      delayed post-polypectomy bleeding. Emergency visits and hospital discharge summaries will be&#xD;
      scanned for up to 6 months after colonoscopy for recurrent cardiothrombotic events. A 24-hour&#xD;
      hotline will be provided for patients to report any adverse or serious events.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2012</start_date>
  <completion_date type="Actual">April 2018</completion_date>
  <primary_completion_date type="Actual">April 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Delayed post-polypectomy bleeding</measure>
    <time_frame>30 days post-colonoscopy</time_frame>
    <description>The primary endpoint is delayed post-polypectomy bleeding. The latter is defined as rectal bleeding, starting after the colonoscope has been retracted from the anus to 30 days after the procedure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immediate post-polypectomy bleeding</measure>
    <time_frame>Within 5 minutes after polypectomy</time_frame>
    <description>bleeding at the time of polypectomy that persists despite continuous irrigation with diluted epinephrine solution for 5 minutes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious Cardiothrombotic events</measure>
    <time_frame>6 months after colonoscopy</time_frame>
    <description>defined according to the antithrombotic trialists' criteria</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">216</enrollment>
  <condition>Gastrointestinal Bleeding</condition>
  <arm_group>
    <arm_group_label>Clopidogrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Continue clopidogrel for 7 days prior to the endoscopic procedure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo daily for 7 days prior to the endoscopic procedure</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clopidogrel</intervention_name>
    <description>Clopidogrel 7 days prior to the endoscopic procedure (Colonoscopy)</description>
    <arm_group_label>Clopidogrel</arm_group_label>
    <other_name>Plavix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for 7 days prior to the endoscopic procedure (Colonoscopy)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. On regular treatment with clopidogrel alone or in combination with other anti-platelet&#xD;
             drugs (e.g. aspirin)&#xD;
&#xD;
          2. Elective colonoscopy for asymptomatic screening of bowel cancer or investigation of&#xD;
             bowel symptoms (e.g. altered bowel habit, rectal bleeding, anemia, polyp follow-up)&#xD;
&#xD;
          3. Age â‰¥ 18&#xD;
&#xD;
          4. Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Coronary stent of any type placed within 30 days&#xD;
&#xD;
          2. Cardiac-vascular event within 3 months&#xD;
&#xD;
          3. Drug-eluting coronary stent placed within 6 months&#xD;
&#xD;
          4. Terminal illness&#xD;
&#xD;
          5. Concomitant use of anticoagulants&#xD;
&#xD;
          6. Congenital or acquired bleeding diathesis showing clinical bleeding tendency (e.g.&#xD;
             hemophilia, decompensated cirrhosis)&#xD;
&#xD;
          7. Pregnancy or women of child-bearing age without regular use of contraception&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francis KL Chan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CUHK</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Hong Kong</city>
        <state>Hong Kong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>March 4, 2013</study_first_submitted>
  <study_first_submitted_qc>March 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2013</study_first_posted>
  <last_update_submitted>January 29, 2019</last_update_submitted>
  <last_update_submitted_qc>January 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Francis KL Chan</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Hemorrhage</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

